Atrosab
Based on 1 publication(s) in Google Scholar
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.94%
- CAS. Nr.: 1365659-05-7
- Molecular Weight:145.837 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Atrosab
MoreAlle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Human IgG1 kappa
Human
TNFR1
Atrosab (0.1-1000 nM, preincubate with antibody for 1 h, then add the stimulant TNF and co-incubate for 7 hours) inhibits in a dose-dependent manner the TNF-induced apoptosis of Kym-1 cells [1].
Atrosab (0.1-1000 nM, preincubate with antibody for 1 h, then add the stimulant TNF and co-incubate for 7 hours) inhibits release of IL-6 from HeLa cells and IL-8 from HT1080 cells induced by TNF dose-dependently[1].
Atrosab (100 μg/mL,24 h) reduces endothelial cell expression of adhesion molecules and T cell adhesion[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Kym-1 cells
-
Concentration:0.1-1 μM
-
Incubation Time:preincubate with antibody for 1 h, then add the stimulant TNF and co-incubate for 7 hours
-
Result:Exhibited half-maximal cytotoxicity at 60 nM in Kym-1 cells.
Inhibited IL-6 release from HeLa cells with an IC50 of 60 nM.
Inhibited IL-8 release from HT1080 cells with an IC50 of 60 nM.
Atrosab (20 mg/kg, i.p.) reduces immune cell infiltrates in humanized TNFR1 knock-in mice [3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CIA rhesus monkey model[2].
-
Dosage:
-
Administration:i.v., twice weekly, 28 days
-
Result:Reduced of the acute-phase C-reactive protein (CRP) and IL-6 in serum.
Improved the clinical arthritis score, delayed the onset of symptoms, and inhibited cartilage degradation.
-
Animal Model:Human TNF transgenic/human TNFR1 Knock-in mice model (Tg197/hp55K/i) for arthritis and human TNFR1 Knock in mice (hp55K/i) EAE model for multiple sclerosis(MS)[2].
-
Dosage:
-
Administration:i.v., twice weekly, 28 days
-
Result:Significantly reduced arthritic pathology and the underlying histopathological lesions in rheumatoid arthritis (RA) mice.
Abolished the development of paralytic symptoms without affecting the overall health status of the animals in EAE mice model of MS.
Showed to be effective for treatment of inflammatory diseases such as RA and MS.
-
Animal Model:humanized TNFR1 knock-in mice[3].
-
Dosage:20 mg/kg
-
Administration:i.p., four times (on days 1, 4, 8 and 12 of manifest EAE)
-
Result:Significantly prevented EAE-associated weight loss.
Led less spinal cord demyelination.
Reduced accumulated amyloid precursor protein (APP), a marker of axonal injury.
Reduced numbers of CD3+ T cells, Mac-3+ activated microglia/macrophages and CD45R+ B cells.
Reduced immune cell infiltration.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 FaDu cells with Atrosab (HY-P990008, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized Human TNFR1,His Tag can bind Atrosab. The EC50 for this effect is 8.161 ng/mL. -
Loaded Atrosab on AHC2 biosensor, can bind TNFRSF1A Protein, Human (His, HY-P70801) with an affinity constant of 1.151E-08 M as determined in BLI assay.
Chemical Information
-
CAS. Nr. 1365659-05-7
-
Appearance Liquid
-
Molecular Weight 145.837 kDa
-
Color Colorless to light yellow
-
SMILES
[Atrosab]
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Commun Signal
Helicobacter pylori infection promotes M1 macrophage polarization and gastric inflammation by activation of NLRP3 inflammasome via TNF/TNFR1 axis. [Abstract]2025 Jan 6;23(1):6. PMID: 39762835
Reinheit & Dokumentation
-
Data Sheet (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010 Nov-Dec;2(6):639-47. [Content Brief]
[2]. Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. [Content Brief]
[4]. Williams SK, et al. Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Sci Rep. 2018 Sep 11;8(1):13628. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Atrosab Related Classifications
HY-P990008 Related Classifications
Powered by Bioz